tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Fungemia D016469 2 associated lipids
Legionellosis D007876 3 associated lipids
Lung Abscess D008169 1 associated lipids
IgA Deficiency D017098 2 associated lipids
IgG Deficiency D017099 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
Alopecia Areata D000506 6 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Polymyositis D017285 1 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Blepharitis D001762 4 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Erythema Nodosum D004893 5 associated lipids
Sweet Syndrome D016463 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Deglutition Disorders D003680 2 associated lipids
Oral Ulcer D019226 1 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Epididymitis D004823 1 associated lipids
Orchitis D009920 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Citrullinemia D020159 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Hand Injuries D006230 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Pemphigus D010392 3 associated lipids
Mutism D009155 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Intestinal Atresia D007409 3 associated lipids
Priapism D011317 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Trichomonas Infections D014245 3 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
West Nile Fever D014901 1 associated lipids
Foot Ulcer D016523 4 associated lipids
Fibroadenoma D018226 2 associated lipids
Tinea Capitis D014006 1 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Lymphocele D008210 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Angiofibroma D018322 2 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Cheilitis D002613 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Optic Neuritis D009902 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Balanitis D001446 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Cacciarelli TV et al. An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1999 Transplantation pmid:10507484
Jain A et al. Pregnancy after liver transplantation under tacrolimus. 1997 Transplantation pmid:9293865
Burroughs TE et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. 2007 Transplantation pmid:17452891
Busuttil RW and Lake JR Role of tacrolimus in the evolution of liver transplantation. 2004 Transplantation pmid:15201686
Gjertson DW et al. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. 1995 Transplantation pmid:8545861
Vincenti F A decade of progress in kidney transplantation. 2004 Transplantation pmid:15201687
Shirakata Y et al. Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. 1995 Transplantation pmid:8545894
Burke GW et al. Advances in pancreas transplantation. 2004 Transplantation pmid:15201688
Bunnapradist S et al. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. 2003 Transplantation pmid:12865780
Garrity ER and Mehra MR An update on clinical outcomes in heart and lung transplantation. 2004 Transplantation pmid:15201689
Pfitzmann R et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. 2003 Transplantation pmid:12865798
Takaya S et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. 1992 Transplantation pmid:1371195
Méndez A et al. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. 2014 Transplantation pmid:24492423
Moss MC et al. Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible? 2014 Transplantation pmid:24492429
Fridell JA et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. 2006 Transplantation pmid:16906038
Boldt A et al. The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo. 2006 Transplantation pmid:16906043
Kuypers DR et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. 2010 Transplantation pmid:20555228
Narayanan M et al. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. 2013 Transplantation pmid:23423268
Sheikh AM et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. 1999 Transplantation pmid:10440408
Gaber AO et al. Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. 2013 Transplantation pmid:23423269
Moffatt SD et al. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. 1999 Transplantation pmid:10342309
Hougardy JM et al. The once-daily formulation of tacrolimus: a step forward in kidney transplantation? 2012 Transplantation pmid:22234346
Fujita T et al. Prolonged survival of rat skin allograft by treatment with FK506 ointment. 1997 Transplantation pmid:9326422
Pratschke J et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. 1997 Transplantation pmid:9326428
Yoshihara S et al. Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. 2004 Transplantation pmid:15077022
Krentz AJ et al. Postoperative glucose metabolism in liver transplant recipients. A two-year prospective randomized study of cyclosporine versus FK506. 1994 Transplantation pmid:7516590
Jain AB et al. Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. 2004 Transplantation pmid:15077034
High KP The antimicrobial activities of cyclosporine, FK506, and rapamycin. 1994 Transplantation pmid:7517076
Gonwa T et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. 2003 Transplantation pmid:12829910
Briggs D et al. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients. 2003 Transplantation pmid:12829912
Jain A et al. Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection. 2014 Transplantation pmid:25285953
Utsugi R et al. Induction of transplantation tolerance with a short course of tacrolimus (FK506): I. Rapid and stable tolerance to two-haplotype fully mhc-mismatched kidney allografts in miniature swine. 2001 Transplantation pmid:11391221
Yin DP et al. Lewis rat pancreas, but not cardiac xenografts, are resistant to anti-gal antibody mediated hyperacute rejection. 2001 Transplantation pmid:11391223
Krentz AJ Posttransplantation Diabetes Mellitus in FK-506-Treated Renal Transplant Recipients: Analysis of Incidence and Risk Factors. Transplantation 2001; 72: 1655. 2001 Transplantation pmid:11726815
Bruce DS et al. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. 2001 Transplantation pmid:11726823
Maes BD et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. 2001 Transplantation pmid:11726827
Sanchez-Campos S et al. Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. 1998 Transplantation pmid:9679826
Egeland EJ et al. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. 2017 Transplantation pmid:28452920
Hsiau M et al. Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. 2011 Transplantation pmid:21857278
Yates CJ et al. Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. 2013 Transplantation pmid:23902993
Jordan ML et al. Long-term results of pancreas transplantation under tacrolius immunosuppression. 1999 Transplantation pmid:10075592
Shapiro R et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. 1999 Transplantation pmid:10075598
Kaplan B et al. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. 1996 Transplantation pmid:8900321
Min DI et al. Circadian variation of tacrolimus disposition in liver allograft recipients. 1996 Transplantation pmid:8900327
Bronster DJ et al. Tacrolimus-associated mutism after orthotopic liver transplantation. 2000 Transplantation pmid:11014653
Jindal RM et al. Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. 1994 Transplantation pmid:7519799
Newell KA et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. 1996 Transplantation pmid:8779685
Lufft V et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. 1996 Transplantation pmid:8779695
Nobori S et al. Long-term acceptance of fully allogeneic cardiac grafts by cotransplantation of vascularized thymus in miniature swine. 2006 Transplantation pmid:16421473
Yu S et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. 2006 Transplantation pmid:16421475
Theruvath TP et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. 2001 Transplantation pmid:11468538
Borrows R et al. Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. 2006 Transplantation pmid:16421488
Arzouk N et al. Interaction between tacrolimus and fumagillin in two kidney transplant recipients. 2006 Transplantation pmid:16421493
Muraki T et al. Effects of cyclosporine and FK506 on in vitro high shear-induced platelet reactivity in rat and human non-anticoagulated blood. 1998 Transplantation pmid:9583878
Kadry Z et al. Kaposi's sarcoma in liver transplant recipients on FK506. 1998 Transplantation pmid:9583882
Luan FL et al. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. 2011 Transplantation pmid:21242885
Ninova D et al. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. 2004 Transplantation pmid:15316360
Ho ET et al. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. 2013 Transplantation pmid:23542469
Shapiro R et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. 2008 Transplantation pmid:18431232
Porrini E et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. 2008 Transplantation pmid:18431233
Veroux M et al. Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. 2012 Transplantation pmid:22298033
Naesens M et al. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. 2008 Transplantation pmid:18431234
Dean PG et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. 2008 Transplantation pmid:18431244
Laskow DA et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8878381
Shoji T et al. Operational tolerance to class I disparate lungs can be induced despite pretransplant immunization with class I allopeptides. 2007 Transplantation pmid:18091523
Inoue T et al. Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats. 2000 Transplantation pmid:11003356
McLaren A Tacrolimus pharmacogenetics: bringing the laboratory into the clinic. 2003 Transplantation pmid:14705621
Roberts CA et al. Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. 2002 Transplantation pmid:12364862
Brunet M et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. 2006 Transplantation pmid:16495801
Kessler L et al. Tacrolimus-associated optic neuropathy after pancreatic islet transplantation using a sirolimus/tacrolimus immunosuppressive regimen. 2006 Transplantation pmid:16495816
Holt S and Moore K Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. 2002 Transplantation pmid:11907407
Yang H et al. Liposomal encapsulation significantly enchances the immunosuppressive effect of tacrolimus in a discordant islet xenotransplant model. 2002 Transplantation pmid:11907415
Klein IH et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. 2002 Transplantation pmid:11907418
St A Nunes FA and Lucey MR Searching for a balance when applying immunosuppression after liver transplantation. 2001 Transplantation pmid:11258425
Vincenti F et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. 2002 Transplantation pmid:11907427
Ringe B et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. 2001 Transplantation pmid:11258429
Meiser BM The best dosing for initial tacrolimus application is trough level adapted! 2005 Transplantation pmid:15714162
Podesser BK et al. Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study. 2005 Transplantation pmid:15714171
Cantarovich D et al. Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. 2005 Transplantation pmid:15714172
Hougardy JM et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. 2011 Transplantation pmid:21192316
Apanay DC et al. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. 1994 Transplantation pmid:7524202
Neuhaus P et al. Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial. 2000 Transplantation pmid:10868638
Steinmüller TM et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. 1994 Transplantation pmid:7524203
Singh N et al. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. 1994 Transplantation pmid:7524204
Mohamed MA et al. TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. 2000 Transplantation pmid:10755567
Sonoda T et al. Outcome of 3 years of immunosuppression with tacrolimus in more than 1,000 renal transplant recipients in japan. 2003 Transplantation pmid:12548123
Roberti I et al. Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. 1992 Transplantation pmid:1384182
Langrehr JM et al. Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. 1992 Transplantation pmid:1384185
Guthery SL et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. 2003 Transplantation pmid:12698085
Jain A et al. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. 2003 Transplantation pmid:12698091
Egashira K et al. Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. 2003 Transplantation pmid:12698101
Peng Y et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. 2013 Transplantation pmid:23263506
Kuypers DR et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. 2013 Transplantation pmid:23263559
Przepiorka D et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. 1996 Transplantation pmid:8990368
White M et al. Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. 2006 Transplantation pmid:17006323
Murase N et al. Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. 1993 Transplantation pmid:7678353
Herold KC et al. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. 1993 Transplantation pmid:7678356
Holman MJ et al. FK506-associated thrombotic thrombocytopenic purpura. 1993 Transplantation pmid:7678357
Markus PM et al. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. 1991 Transplantation pmid:1718063
Chan L et al. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. 2010 Transplantation pmid:20517177